Novel inhalation therapies for rare lung diseases
Giving lung patients with unmet medical needs an option.
GM-CSF & Factor VIIa
We develop inhalable medicines for the treatment of patients with severe pulmonary conditions. We focus on two biologic compounds – GM-CSF and Factor VIIa.
About our focus
We focus on respiratory conditions such as PAP (pulmonary alveolar proteinosis), ARDS (acute respiratory distress syndrome) and DAH (diffuse alveolar hemorrhage).
Serendex at a glance
The what, who, where, why and how for Serendex Pharmaceuticals A/S. Learn more about our company by reading our corporate factsheet.
Annual Results 2015
Get up to date on Serendex Pharmaceuticals A/S. Download our Annual Report 2015 and read more about our pipeline progress and business outlook.
Annual Report 2015
PAP Information Brochure
Learn more about or key indication PAP (pulmonary alveolar proteinosis) by reading this information brochure developed in collaboration with medical experts.